Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - somatropin, quantity: 4.8 mg/ml - injection, powder for - excipient ingredients: glycine; mannitol; monobasic sodium phosphate; dibasic sodium phosphate - indications: short stature due to decreased or failed secretion of pituitary growth hormone. indications as at 13 june 2003: short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. for treatment of growth disturbance in children with chronic renal insufficiency whose height is on or less than twenty-fifth percentile and whose growth velocity is on or less than twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 50 ml/min/1.73m2.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - somatropin, quantity: 5.6 mg/ml - injection, powder for - excipient ingredients: glycine; mannitol; monobasic sodium phosphate; dibasic sodium phosphate - indications: short stature due to decreased or failed secretion of pituitary growth hormone. indications as at 13 june 2003: short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. for treatment of growth disturbance in children with chronic renal insufficiency whose height is on or less than twenty-fifth percentile and whose growth velocity is on or less than twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 50 ml/min/1.73m2.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - somatropin, quantity: 6.4 mg/ml - injection, powder for - excipient ingredients: glycine; mannitol; monobasic sodium phosphate; dibasic sodium phosphate - indications as at 13 june 2003: short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. for treatment of growth disturbance in children with chronic renal insufficiency whose height is on or less than twenty-fifth percentile and whose growth velocity is on or less than twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 50 ml/min/1.73m2.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - somatropin, quantity: 7.2 mg/ml - injection, powder for - excipient ingredients: glycine; mannitol; monobasic sodium phosphate; dibasic sodium phosphate - indications as at 13 june 2003: short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. for treatment of growth disturbance in children with chronic renal insufficiency whose height is on or less than twenty-fifth percentile and whose growth velocity is on or less than twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 50 ml/min/1.73m2.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - somatropin, quantity: 8 mg/ml - injection, powder for - excipient ingredients: glycine; mannitol; monobasic sodium phosphate; dibasic sodium phosphate - indications as at 13 june 2003: short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. for treatment of growth disturbance in children with chronic renal insufficiency whose height is on or less than twenty-fifth percentile and whose growth velocity is on or less than twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 50 ml/min/1.73m2.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - somatropin -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - somatropin -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - somatropin -

Združene države Amerike - angleščina - NLM (National Library of Medicine)

liddell laboratories, inc. - somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl), beef liver (unii: w8n8r55022) (beef liver - unii:w8n8r55022), bos taurus pituitary gland (unii: 7jm57i419k) (bos taurus pituitary gland - unii:7jm57i419k) - somatropin 30 [hp_x] in 1 ml - indications:   temporarily supports the body to rebalance human growth hormone (hgh) output.  symptoms of imbalanced hgh may include:  poor muscle/fat balance, dry wrinkled-skin, low energy, sleeplessness, weak immune system. indications:   temporarily supports the body to rebalance human growth hormone (hgh) output.  symptoms of imbalanced hgh may include:  poor muscle/fat balance, dry wrinkled skin, low energy, sleeplessness, weak immune system.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

ohm pharma inc. - somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl), dalotuzumab (unii: 6yi1l648rh) (dalotuzumab - unii:6yi1l648rh), saccharomyces cerevisiae rna (unii: j17gbz5vgx) (saccharomyces cerevisiae rna - unii:j17gbz5vgx), herring sperm dna (unii: 51fi676n6f) (herring sperm dna - unii:51fi676n6f), sus scrofa adrenal gland (unii: 398iyq16yv) (sus scrofa adrenal gland - unii:398iyq16yv), pork liver (unii: 6ec706hi7f) (pork liver - unii:6ec706hi7f), sus scrofa pituitary gland (unii: e8s87o660t) (sus sc - somatropin 6 [hp_x] in 30 ml - uses : temporarily relieves symptoms of low energy and immune system imbalance.